文献速递乳腺癌头颈与中枢神经肿瘤骨软组织肉瘤与黑色素瘤

网络引导建模可实现肿瘤类型无关的全反式维甲酸敏感性预测

Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid.
PubMed 文献 · Ann Oncol · 2017-01-01

研究利用TCGA与Leucegene共10080例患者、33种肿瘤类型的RNA测序数据,以机器学习与网络分析构建ATRA敏感性预测模型。模型ATRA-21在多种肿瘤细胞系中与实验敏感性相关,可识别急性早幼粒细胞白血病为最敏感AML亚型,并提示葡萄膜黑色素瘤与低级别胶质瘤平均预测敏感性居前。

要点

  • ATRA-21为基于有限数量基因的肿瘤类型无关ATRA敏感性预测模型
  • 模型正确识别急性早幼粒细胞白血病为最敏感的急性髓系白血病亚型
  • 多种肿瘤中较高ATRA-21预测值与更好结局相关

核心结论

  • 研究构建了肿瘤类型无关的ATRA敏感性预测模型ATRA-21,由有限数量基因组成,具临床应用潜力;识别可能普遍对ATRA敏感的肿瘤类型为相关临床研究设计铺路,ATRA-21或可帮助筛选可能从ATRA治疗策略获益的个体患者。

研究设计与样本

  • 研究基于TCGA与Leucegene数据集的10080例患者、33种不同肿瘤类型的RNA测序数据,数据经完全重新处理,采用机器学习方法与网络分析开展。
  • 先对大型乳腺癌细胞系panel进行ATRA体外敏感性分析,并利用相关基线基因表达数据构建乳腺癌ATRA敏感性预测模型,再以网络引导方法推广为通用模型ATRA-21。

主要发现

  • ATRA-21预测值与代表多种肿瘤类型的大型细胞系panel中实验测定的敏感性相关。
  • 在患者中,ATRA-21正确识别急性早幼粒细胞白血病为最敏感的急性髓系白血病亚型,并提示葡萄膜黑色素瘤与低级别胶质瘤为平均预测ATRA反应性排名最前的疾病。
  • 存在相当数量的肿瘤类型,其较高ATRA-21预测值与更好结局相关。

临床怎么用

  • 作者认为ATRA-21具临床应用潜力,并可成为筛选可能从ATRA治疗策略获益患者的诊断工具,包括平均敏感性较低的肿瘤。
  • 作者指出识别可能普遍对ATRA敏感的肿瘤类型为在这些疾病中设计临床研究铺路。

局限性

  • 原文未报告局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: All-trans-retinoic acid (ATRA) is a differentiating agent used in the treatment of acute-promyelocytic-leukemia (APL) and it is under-exploited in other malignancies despite its low systemic toxicity. A rational/personalized use of ATRA requires the development of predictive tools allowing identification of sensitive cancer types and responsive individuals. MATERIALS AND METHODS: RNA-sequencing data for 10 080 patients and 33 different tumor types were derived from the TCGA and Leucegene datasets and completely re-processed. The study was carried out using machine learning methods and network analysis. RESULTS: We profiled a large panel of breast-cancer cell-lines for in vitro sensitivity to ATRA and exploited the associated basal gene-expression data to initially generate a model predicting ATRA-sensitivity in this disease. Starting from these results and using a network-guided approach, we developed a generalized model (ATRA-21) whose validity extends to tumor types other than breast cancer. ATRA-21 predictions correlate with experimentally determined sensitivity in a large panel of cell-lines representative of numerous tumor types. In patients, ATRA-21 correctly identifies APL as the most sensitive acute-myelogenous-leukemia subtype and indicates that uveal-melanoma and low-grade glioma are top-ranking diseases as for average predicted responsiveness to ATRA. There is a consistent number of tumor types for which higher ATRA-21 predictions are associated with better outcomes. CONCLUSIONS: In summary, we generated a tumor-type independent ATRA-sensitivity predictor which consists of a restricted number of genes and has the potential to be applied in the clinics. Identification of the tumor types that are likely to be generally sensitive to the action of ATRA paves the way to the design of clinical studies in the context of these diseases. In addition, ATRA-21 may represent an important diagnostic tool for the selection of individual patients who may benefit from ATRA-based therapeutic strategies also in tumors characterized by lower average sensitivity.

来源:Ann Oncol,查看原文。版权归原作者所有。

引用

  1. Bolis M, Garattini E, Paroni G, et al. Network-guided modeling allows tumor-type independent prediction of sensitivity to all-trans-retinoic acid. Ann Oncol. 2017. PMID: 27993792. doi:10.1093/annonc/mdw660

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。